August 11, 2009
[VIDEO] Provectus Pharmaceuticals Updates Shareholders on 2009 Year-to-date Accomplishments

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) Provectus reports on its year-to-date clinical and corporate accomplishments in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.

Read the complete article here.

July 20, 2009
Provectus Pharmaceuticals Initiates New PH-10 Clinical Study for Psoriasis

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. The new study supplants an earlier Phase 2 study, using twice weekly dosing for 12 weeks, which was terminated earlier in June.

Read the complete article here.

July 1, 2009
Provectus Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is the Company's topical drug for the treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition that includes some forms of eczema.

Read the complete article here.

June 22, 2009
Provectus Pharmaceuticals to Offer Compassionate Use of PV-10 for Non-Visceral Indications in Cancer Patients

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients.

Read the complete article here.

June 19, 2009
Provectus Reports on Shareholders Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) held its 2009 Annual Meeting of Shareholders on Thursday, June 18, 2009 in Knoxville, Tennessee. Shareholders voted to re-elect the Company's five members of the Board of Directors, which is composed of three inside directors, and two outside directors.

Read the complete article here.

June 1, 2009
PROVECTUS REPORTS ENCOURAGING CLINICAL DATA AT ASCO ON TREATMENT OF METASTATIC MELANOMA WITH PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and elicited selective ablation of tumors in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.

Read the complete article here.